NEW

Philips Showcases Tele-Ultrasound at AIUM Virtual Event

Royal Philips announced its participation in the upcoming Annual Integrative Ultrasound Meeting (AIUM) virtual event, April 11-14, hosted by the American Institute of Ultrasound in Medicine.

FUJIFILM Healthcare starts to operate as Fujifilm Group company

Adding CT/MRI and other medical devices to the lineup to globally provide value-added solutions based on medical IT

Hyperfine Launches ‘Total Rethink Buying Process’

Hyperfine Research announced in a press release that it is pioneering a wholesale simplification of the capital equipment purchasing experience with the launch of its Total Rethink Buying Process.

Cardinal Health Launches Navista TS

Cardinal Health Specialty Solutions has launched Cardinal Health Navista™ Tech Solutions (TS), an advanced suite of technology solutions to help community oncologists improve outcomes and costs associated with patient treatment as they transition to value-based care.

The FDA issues Artificial Intelligence and Machine Learning (AI/ML) Software as a Medical Device Action Plan

FDA

Today, the U.S. Food and Drug Administration (FDA) issued the “Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan” from the Center for Devices and Radiological Health’s Digital Health Center of Excellence.

The Action Plan is a direct response to stakeholder feedback to the April 2019 discussion paper, “Proposed Regulatory Framework for Modifications to Artificial Intelligence/Machine Learning-Based Software as a Medical Device” and outlines five actions the FDA intends to take, which include:

  • Further developing the proposed regulatory framework, including issuing draft guidance on a predetermined change control plan;
  • Supporting the development of good machine learning practices to evaluate and improve machine learning algorithms;
  • Fostering a patient-centered approach, including device transparency to users;
  • Developing methods to evaluate and improve machine learning algorithms; and
  • Advancing real-world performance monitoring pilots.

AI/ML-based SaMD is a rapidly progressing field and the FDA anticipates this action plan will continue to evolve. The FDA welcomes continued feedback in this area and looks forward to engaging with stakeholders on these efforts. We will also continue to collaborate across the FDA to build a coordinated approach in areas of common focus related to AI/ML.

READ THE ACTION PLAN »

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *